Compendium: Management of Viral Hemorrhagic Fever (Viral Fever), Involving Its Pathogenesis

Yash Srivastav *

Azad Institute of Pharmacy & Research, Lucknow, U.P, India.

Aniket Kumar

Azad Institute of Pharmacy & Research, Lucknow, U.P, India.

Jaya Singh

Tahira Institute of Medical Science, Gorakhpur, U.P, India.

Aditya Srivastav

Azad Institute of Pharmacy & Research, Lucknow, U.P, India.

Mohd. Imtiyaz Ahmad

Azad Institute of Pharmacy & Research, Lucknow, U.P, India.

*Author to whom correspondence should be addressed.


Abstract

The term "Viral Hemorrhagic Fever" (VHF) describes a severe feverish sickness characterized by aberrant vascular control, vascular damage, and hemorrhagic symptoms. Multiple viruses belonging to distinct families are the cause of this illness. The viruses that cause VHF are categorized into seven distinct families according to the International Committee on Taxonomy of Viruses' most recent classification: Hantaviridae, Nairoviridae, Filoviridae, Phenuiviridae, Paramyxoviridae, Arenavidae, and Flaviviridae are the families involved. The concept of virus hemorrhagic fevers (VHFs) originated in the 1930s when Soviet researchers were studying hantaviral hemorrhagic fever (HF) with renal dysfunction. Dengue fever/Dengue haemorrhagic fever and Kyasanur forest sickness are the two most common viral hemorrhagic fevers (VHF) in India that are transmitted by arthropod vectors. The diagnosis of community-acquired pneumonia (CCHF) in India is greatly hampered by the co-occurring symptoms of hemorrhagic fevers such as dengue, Kyasanur forest sickness, Hantavirus hemorrhagic fever, and other illnesses such as leptospirosis, meningococcal infections, and malaria. The pathophysiology, aetiology, diagnosis, treatment, symptoms, and indicators of virus hemorrhagic fevers (VHFs) are all covered in this review article.

Keywords: Virus Hemorrhagic Fevers (VHFs), epidemiology, etiology, pathogenesis, management


How to Cite

Srivastav, Y., Kumar , A., Singh, J., Srivastav , A., & Ahmad , M. I. (2024). Compendium: Management of Viral Hemorrhagic Fever (Viral Fever), Involving Its Pathogenesis. Asian Journal of Research in Infectious Diseases, 15(3), 17–25. https://doi.org/10.9734/ajrid/2024/v15i3334

Downloads

Download data is not yet available.

References

Zapata JC, Cox D, Salvato MS. The Role of Platelets in the Pathogenesis of Viral Hemorrhagic Fevers. PLoS Negl Trop Dis. 2014;8(6).

Schnittler HJ, Feldmann H. Viral hemorrhagic fever - A vascular disease? Thromb Haemost. 2003;89(6):967–72.

Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, et al. Fruit bats as reservoirs of Ebola virus. Nature. 2005;438(7068):575–6.

Rodas CMR and JD. Epidemiological Surveillance of Viral Hemorrhagic Fevers With Emphasis on Clinical Virology. 2018;1604.

Mariappan V, Pratheesh P, Shanmugam L, Rao SR, Pillai AB. Viral hemorrhagic fever: Molecular pathogenesis and current trends of disease management-an update. Curr Res Virol Sci [Internet]. 2021;2: 100009. Available:https://www.sciencedirect.com/science/article/pii/S2666478X21000039

Bhalla DA. Association of Physicians of India Indian College of Physicians; 100.

Samaranayake L, Scully C, Nair RG, Petti S. Viral haemorrhagic fevers with emphasis on Ebola virus disease and oro-dental healthcare. Oral Dis. 2015;21(1): 1–6.

Asogun DA, Günther S, Akpede GO, Ihekweazu C, Zumla A. Lassa fever: Epidemiology, clinical features, diagnosis, management and prevention. Infect Dis Clin North Am. 2019;33(4):933–51.

Hidalgo J, Richards GA, Jiménez JIS, Baker T, Amin P. Viral hemorrhagic fever in the tropics: Report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine. J Crit Care [Internet]. 2017;42:366–72. Available:https://doi.org/10.1016/j.jcrc.2017.11.006

Bente DA, Forrester NL, Watts DM, McAuley AJ, Whitehouse CA, Bray M. Crimean-Congo hemorrhagic fever: History, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res [Internet]. 2013;100(1):159–89. Available:http://dx.doi.org/10.1016/j.antiviral.2013.07.006

Iannetta M, Di Caro A, Nicastri E, Vairo F, Masanja H, Kobinger G, et al. Viral Hemorrhagic Fevers Other than Ebola and Lassa. Infect Dis Clin North Am. 2019;33(4):977–1002.

Rougeron V, Feldmann H, Grard G, Becker S, Leroy EM. Ebola and Marburg haemorrhagic fever. J Clin Virol [Internet]. 2015;64:111–9. Available:http://dx.doi.org/10.1016/j.jcv.2015.01.014

Kularatne SAM. Dengue fever. BMJ. 2015;351(September):1–10.

Mangat R, Louie T. Viral Hemorrhagic Fevers. [Updated 2023 Aug 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available:https://www.ncbi.nlm.nih.gov/books/NBK560717/. 2024;560717.

Bausch DG. 194 . Viral hemorrhagic fevers. 2019;

Fhogartaigh CN, Aarons E. Viral haemorrhagic fever. Clin Med J R Coll Physicians London. 2015;15(1):61–6.

Chen ZH, Qin XC, Song R, Shen Y, Chen XP, Wang W, et al. Co-circulation of multiple hemorrhagic fever diseases with distinct clinical characteristics in Dandong, China. PLoS One. 2014;9(2).

Liu JW, Lee IK, Wang L, Chen RF, Yang KD. The usefulness of clinical-practice-based laboratory data in facilitating the diagnosis of dengue illness. Biomed Res Int. 2013;2013.

Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, et al. The Use of TKM-100802 and Convalescent Plasma in 2 Patients with Ebola Virus Disease in the United States. Clin Infect Dis. 2015;61(4):496–502.

Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis. 2007;196(SUPPL. 2).

Epelboin L, Boullé C, Ouar-Epelboin S, Hanf M, Dussart P, Djossou F, et al. Discriminating malaria from dengue fever in endemic areas: Clinical and biological criteria, prognostic score and utility of the c-reactive protein: A retrospective matched-pair study in french Guiana. PLoS Negl Trop Dis. 2013;7(9).

Bukbuk DN, Fukushi S, Tani H, Yoshikawa T, Taniguchi S, Iha K, et al. Development and validation of serological assays for viral hemorrhagic fevers and determination of the prevalence of rift valley fever in Borno State, Nigeria. Trans R Soc Trop Med Hyg. 2014;108(12):768–73.

Ibekwe T, Nwegbu M, Okokhere P, Adomeh D, Asogun D. The sensitivity and specificity of Lassa virus IgM by ELISA as screening tool at early phase of Lassa fever infection. Niger Med J. 2012;53(4):196.

Centre SAC of the HPS. The Management of Viral Haemorrhagic Fevers in Ireland. 2012; Available:http://www.hpsc.ie/A-Z/Vectorborne/ViralHaemorrhagicFever/Guidance/File,12936, en.pdf

Mehedi M, Groseth A, Feldmann H, Ebihara H. Clinical aspects of Marburg hemorrhagic fever. Future Virol. 2011;6(9):1091–106.

DAB, NLF, DMW, AJM, CA. WM.B. Crimean-Congo hemorrhagic fever: History, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res [Internet]. 2013;100(1):159–89. Available:http://0-ovidsp.ovid.com.wam. city.ac.uk/ovidweb.cgi?T=JS&PAGE =reference& D=emed11&NEWS=N&AN=2013741328

Racsa LD, Kraft CS, Olinger GG, Hensley LE. Viral hemorrhagic fever diagnostics. Clin Infect Dis. 2016;62(2):214–9.

Ippolito G, Feldmann H, Lanini S, Vairo F, Di Caro A, Capobianchi MR, et al. Viral hemorrhagic fevers: Advancing the level of treatment. BMC Med. 2012; 10.

Bolken TC, Laquerre S, Zhang Y, Bailey TR, Pevear DC, Kickner SS, et al. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res. 2006;69(2):86–97.

Lee AM, Pasquato A, Kunz S. Novel approaches in anti-arenaviral drug development. Virology [Internet]. 2011;411(2):163–9. Available:http://dx.doi.org/10.1016/j.virol.2010.11.022

Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009;82(3):95–102.

Pasquato A, Rochat C, Burri DJ, Pasqual G, La Torre JC de, Kunz S. Evaluation of the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-429242. Virology [Internet]. 2012; 423(1):14–22.

Available:http://dx.doi.org/10.1016/j.virol.2011.11.008

Urata S, Yun N, Pasquato A, Paessler S, Kunz S, de la Torre JC. Antiviral Activity of a Small-Molecule Inhibitor of Arenavirus Glycoprotein Processing by the Cellular Site 1 Protease. J Virol. 2011;85(2):795–803.

Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, et al. Identification of a Small-Molecule Entry Inhibitor for Filoviruses. J Virol. 2011;85(7):3106–19.

Vincent MJ, Sanchez AJ, Erickson BR, Basak A, Chretien M, Seidah NG, et al. Crimean-Congo Hemorrhagic Fever Virus Glycoprotein Proteolytic Processing by Subtilase SKI-1. J Virol. 2003;77 (16):8640–9.

Ollmann Saphire E. A Vaccine against Ebola Virus. Cell [Internet]. 2020;181(1): 6. Available:http://dx.doi.org/10.1016/j.cell.2020.03.011

Rougeron V, Feldmann H, Grard G, Becker S, Leroy EM. Ebola and Marburg haemorrhagic fever. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2015 Mar;64:111–9.

Kularatne SAM. Dengue fever. BMJ. 2015 Sep;351:h4661.

Gubler DJ, Halstead SB. Is Dengvaxia a useful vaccine for dengue endemic areas? BMJ. 2019 Oct;367:l5710.

Mariappan V, Pratheesh P, Shanmugam L, Rao SR, Pillai AB. Viral hemorrhagic fever: Molecular pathogenesis and current trends of disease management-an update. Curr Res Virol Sci [Internet]. 2021;2(July): 100009. Available:https://doi.org/10.1016/j.crviro.2021.100009